Clinical Trials and Research on Young-Onset Colorectal Cancer
Researchers at Dana‑Farber frequently conduct clinical trials on colon cancer and rectal cancer to find better ways to prevent, diagnose, and treat this disease.
The Dana‑Farber Young‑Onset Colorectal Cancer Center conducts clinical trials and research aimed at preventing, diagnosing, and treating young adults (under 50) with colon or rectal cancer. The center focuses on targeted therapies such as KRAS inhibitors, novel chemotherapy agents, antibody‑drug conjugates, and immunotherapies including CAR T‑cell therapy, as well as studies on the microbiome, diet, lifestyle, and screening tools.
Incidence of colorectal cancer among young adults is rising, making it crucial to develop age‑appropriate prevention, diagnostic, and therapeutic strategies. Clinical trials at Dana‑Farber strive to address unmet needs in this emerging population.
Evidence level: Feltételezés / hírjelzés. Nincs önálló tudományos bizonyíték.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics